The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.
September 27th 2024
Shyam A. Patel, MD, PhD, discusses findings from a meta-analysis of the effect of clonal hematopoiesis on outcomes for hematopoietic stem cell transplant.
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
Community Oncology Connections™: Selecting and Sequencing Therapy for Patients With DLBCL in an Era of Expanding Options
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...
November 16, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Serum Biomarkers Are Early Predictors for Haplo-SCT Outcomes
Higher levels of the serum biomarkers ST2 and REG3α were associated with increased incidence of graft-vs-host disease and increased risk for transplant-related mortality in patients who have undergone haploidentical stem-cell transplantation with post-transplant cyclophosphamide.
Pegcetacoplan Outperforms Current Standard of Care in Paroxysmal Nocturnal Hemoglobinuria
June 12th 2020The novel C3 inhibitor pegcetacoplan led to a significant improvement in hemoglobin level and other clinical outcomes at week 16 versus the current standard of care, eculizumab in patients with paroxysmal nocturnal hemoglobinuria.
Experts Provide Tips on Harnessing MRD to Guide ALL Therapy
June 4th 2020During a recent OncLive Peer Exchange®, a panel of experts in adult and pediatric leukemia provided insight on how they use minimal or measurable residual disease (MRD) to guide treatment decisions, including transplantation and choice of therapy in patients who demonstrate MRD positivity after induction and first- and subsequent-line therapies.
Dr. Sekeres on the Need for Novel Combinations in Higher-Risk MDS/CMML and Low-Blast AML
June 4th 2020Mikkael A. Sekeres, MD, discusses the need for novel combinations in higher-risk myelodysplastic syndrome (MDS)/chronic myelomonocytic leukemia (CMML) and low-blast acute myelogenous leukemia (LB AML).
Pevonedistat/Azacitidine Shows Favorable Activity in Higher-Risk MDS/CMML, Low-Blast AML
June 3rd 2020The combination of pevonedistat and azacitidine led to a trend toward improved event-free survival and a numerical improvement in overall survival versus azacitidine alone in patients with higher-risk myelodysplastic syndrome/chronic myelomonocytic leukemia, and low-blast acute myelogenous leukemia.